Since completing a significant funding round supported by notable Chinese investors last year, ZXBio (Yang Zhang ’19) has been making steady progress. The company recently achieved a critical milestone in its effort to enhance the accessibility of high-quality diagnostics in China.
ZXBio has just obtained two Class III medical device registration certificates from China’s National Medical Products Administration (NMPA), the primary regulatory body for medical devices in the country. These approved products are flow cytometry kits that analyze the composition of immune cells in a patient’s blood, offering essential information for diagnosing and monitoring tumors, autoimmune diseases, and infectious diseases. Class III is the most rigorous certification category under NMPA, designated for products with the highest clinical significance, making this approval a significant regulatory accomplishment.
For founder and Yale SOM alumnus Yang Zhang ’19, this milestone holds personal significance. “This is a groundbreaking development in the field in China,” Zhang remarked. ZXBio is now the first company in Huzhou City to possess Class III registrations for this type of diagnostic kits, a distinction with both commercial and symbolic importance. Previously, the Chinese market for these products was dominated by imported goods, but ZXBio’s domestically developed kits offer a high-quality alternative, aligning with the company’s core objective of reducing Chinese patients’ dependence on expensive foreign medical products.
This approval also validates years of scientific research based on Zhang’s academic background. Holding a Ph.D. in Immunology from UCSF, Zhang established ZXBio around proprietary monoclonal antibody technology developed during his research tenure. The company currently holds close to 50 patents and over 140 Chinese medical device filings and registrations.
ZXBio has garnered recognition beyond its home city, being named to the “IVD Innovation Top 100” list in 2025 and selected as a “Deloitte China Pharma & Healthcare Rising Star.” Now, with regulatory approval secured for two flagship diagnostic products, ZXBio is well-positioned to expand its commercial presence and uphold its commitment to delivering precision care for Chinese patients.
